Gain Therapeutics (GANX) Current Leases (2020 - 2026)

Gain Therapeutics has reported Current Leases for 7 years, with the latest figure at $109428.0 in Q2 2026.

• On a quarterly basis, Current Leases fell 19.73% year-over-year to $109428.0 in Q2 2026; TTM through Jun 2026 was $109428.0, a 19.73% decrease from a year earlier, with the FY2025 full-year figure at $119876.0, down 25.5% from the prior year.
• Current Leases was $109428.0 for Q2 2026 at Gain Therapeutics, down from $116627.0 in the prior quarter.
• The five-year high for Current Leases was $235798.0 in Q2 2023, with the low at $109428.0 in Q2 2026.
• Average Current Leases over 5 years is $182766.9, with a median of $195707.5 recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Current Leases jumped 83.22% in 2022, then plunged 35.17% in 2025.
• Over 5 years, Current Leases stood at $229080.0 in 2022, then climbed by 0.27% to $229693.0 in 2023, then fell by 29.94% to $160913.0 in 2024, then dropped by 25.5% to $119876.0 in 2025, then declined by 8.72% to $109428.0 in 2026.
• The last three Current Leases figures came in at $109428.0 (Q2 2026), $116627.0 (Q1 2026), and $119876.0 (Q4 2025), per Business Quant data.